Er Therapeutics Beta vs. Price To Earning
| PNGM Stock | USD 0.0001 0.00 0.00% |
For Er Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Er Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Er Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Er Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Er Therapeutics over time as well as its relative position and ranking within its peers.
PNGM |
Is Diversified Metals & Mining space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Er Therapeutics. If investors know PNGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Er Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.95) |
The market value of Er Therapeutics is measured differently than its book value, which is the value of PNGM that is recorded on the company's balance sheet. Investors also form their own opinion of Er Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Er Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Er Therapeutics' market value can be influenced by many factors that don't directly affect Er Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Er Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Er Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Er Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Er Therapeutics Price To Earning vs. Beta Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Er Therapeutics's current stock value. Our valuation model uses many indicators to compare Er Therapeutics value to that of its competitors to determine the firm's financial worth. Er Therapeutics is considered to be number one stock in beta category among its peers. It also is considered to be number one stock in price to earning category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Er Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.PNGM Price To Earning vs. Beta
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Er Therapeutics |
| = | 10.4 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Er Therapeutics |
| = | (0.06) X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
PNGM Price To Earning Comparison
Er Therapeutics is currently under evaluation in price to earning category among its peers.
Beta Analysis
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Er Therapeutics will likely underperform.
Er Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Er Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Er Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Er Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Er Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -280.2 K | -294.2 K | |
| Net Loss | -384.3 K | -403.5 K | |
| Income Before Tax | -384.3 K | -403.5 K | |
| Total Other Income Expense Net | -104.1 K | -98.9 K | |
| Net Loss | -384.3 K | -403.5 K | |
| Net Loss | -384.3 K | -403.5 K | |
| Change To Netincome | 123.6 K | 129.8 K |
PNGM Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Er Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Er Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Er Therapeutics' important profitability drivers and their relationship over time.
Use Er Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Er Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Er Therapeutics will appreciate offsetting losses from the drop in the long position's value.Er Therapeutics Pair Trading
Er Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Er Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Er Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Er Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Er Therapeutics to buy it.
The correlation of Er Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Er Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Er Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Er Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Er Therapeutics position
In addition to having Er Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Size And Style ETFs Thematic Idea Now
Size And Style ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Size And Style ETFs theme has 1105 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Size And Style ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
To fully project Er Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Er Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Er Therapeutics' income statement, its balance sheet, and the statement of cash flows.